Latest Articles
NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis-mediated Ca²⁺ influx - Nature
NHE7 drives endometrial cancer progression by delaying senescence through cAMP/CREB/GRIN2B axis-mediated Ca²⁺ influx Nature
Published: June 5, 2025, 9:33 p.m.
Epidemiology, Molecular Typing, Microbiome-Immune Interactions and Treatment Strategies of Endometrial Cancer: A Review - Frontiers
Epidemiology, Molecular Typing, Microbiome-Immune Interactions and Treatment Strategies of Endometrial Cancer: A Review Frontiers
Published: June 5, 2025, 1:47 p.m.
SNUBH study finds lymph node dissection unnecessary in some endometrial cancer cases - koreabiomed.com
SNUBH study finds lymph node dissection unnecessary in some endometrial cancer cases koreabiomed.com
Published: June 5, 2025, 3:23 a.m.
LGL: Paula S. Cousins Ovarian and Endometrial Cancer Foundation - yourerie.com
LGL: Paula S. Cousins Ovarian and Endometrial Cancer Foundation yourerie.com
Published: June 4, 2025, 9:50 p.m.
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local - yourerie.com
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local yourerie.com
Published: June 4, 2025, 2:22 p.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com Canada
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com Canada
Published: June 3, 2025, 8:43 a.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com
Published: June 3, 2025, 8:41 a.m.
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer - Insider Monkey
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer Insider Monkey
Published: June 3, 2025, 5 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Link copied to clipboard!